ALSF Childhood Cancer Research Grants
With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,500 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
Project Title | Institution / Principal Investigator(s) | Grant Type | Year | State |
---|---|---|---|---|
Targeting PLK1 as a Common Mechanism in Ph-like ALL | University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD | Reach Grants | 2016 | Texas |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy | New York Medical College / Mitchell Cairo, MD | Reach Grants | 2023 | New York |
Enhancing TKI Therapy in Ph-Like Leukemia | The Regents of the University of California, Irvine / David Fruman, PhD | Reach Grants | 2022 | California |
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma | The Johns Hopkins University School of Medicine / David Loeb, MD, PhD | Reach Grants | 2013 | Maryland |
DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors | University of Illinois, Urbana-Champaign / Michael Spinella, Ph.D. | Reach Grants | 2014 | Illinois |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML | Emory University / Muxiang Zhou, MD | Reach Grants | 2023 | Georgia |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors | Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD | Reach Grants | 2017 | New York |
Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children | Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD | Reach Grants | 2018 | Washington |
Preclinical Development of Targeted Therapy for Neuroblastoma with ALK and CDK4/6 Dual Pathway Inhibition | Children’s Hospital of Philadelphia / Yael Mossé, MD | Reach Grants | 2013 | Pennsylvania |
Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma | The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D. | Reach Grants | 2014 | California |